GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate | PharmExec
GSK Agrees to $357 Million Exclusive License Agreement GSK secures exclusive rights to Syndivia's promising ADC for metastatic castration-resistant prostate cancer, enhancing treatment opt…